CN-121971461-A - Application of saikosaponin B2 in preparing medicament for preventing and/or treating rheumatoid arthritis or acute enteritis

Abstract

The invention provides application of saikosaponin B2 in preparing a medicine for preventing and/or treating rheumatoid arthritis or acute enteritis, belonging to the technical field of natural medicines. The invention discovers that the saikosaponin B2 can be used for preparing the medicine for preventing and/or treating the rheumatoid arthritis or the acute enteritis for the first time, and has wide application prospect.

Inventors

• WANG FEI
• Cao Dongyi
• Xi Ruiying
• JI MINGHUI

Assignees

• 中国科学院成都生物研究所

Dates

Publication Date

20260505

Application Date

20260408

Priority Date

20250410

Claims (10)

1. 1. Use of saikosaponin B2 in preparing medicine for preventing and/or treating rheumatoid arthritis, inflammatory bowel disease, peritonitis or acute enteritis.
2. 2. The use according to claim 1, wherein the inflammatory bowel disease is ulcerative colitis.
3. 3. The use according to claim 1, wherein the medicament is a medicament for alleviating joint swelling.
4. 4. The use according to claim 1, wherein the medicament is a medicament for reducing the inflammatory index.
5. 5. The use according to claim 1, wherein the medicament is a medicament for improving colon length shortening.
6. 6. The use according to claim 1, wherein the medicament is a medicament for improving hematochezia.
7. 7. The use according to claim 1, wherein the medicament is a medicament for improving weight loss.
8. 8. The use according to any one of claims 1 to 7, wherein the medicament is a preparation prepared by adding pharmaceutically acceptable auxiliary materials to Hu Zaogan B2 as an active ingredient.
9. 9. The use according to claim 8, wherein the formulation is an oral formulation.
10. 10. The use according to claim 8, wherein the formulation is an injectable formulation.

Description

Application of saikosaponin B2 in preparing medicament for preventing and/or treating rheumatoid arthritis or acute enteritis Technical Field The invention belongs to the technical field of natural medicines, and particularly relates to application of saikosaponin B2 in preparing medicines for preventing and/or treating rheumatoid arthritis or acute enteritis. Background Rheumatoid arthritis (Rheumatoid Arthritis, RA) is an autoimmune disease characterized by chronic, symmetrical polyarthritis as the main pathological feature. The etiology is not completely elucidated, but it is currently accepted that the disease is a result of the combined action of genetic susceptibility factors (such as HLA-DR4 and other specific genotypes), environmental inducement (such as smoking and infection) and immune system dysfunction. From the clinical manifestation, RA patients often experience persistent joint pain, swelling, morning stiffness (duration often exceeding 30 minutes), most commonly seen with small joints such as wrist, metacarpophalangeal and proximal interphalangeal joints. With the progress of the disease, the joint movement is limited, deformity (such as ulnar deviation and swan neck deformity) and functional loss can occur, and part of patients can also be accompanied with fever, fatigue, rheumatoid nodules, and the involvement of extra-articular organs such as cardiovascular organs, lungs and the like, so that the life quality is seriously affected. At present, clinical treatment of RA still aims at alleviating symptoms and delaying joint destruction. Commonly used drugs include non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, traditional disease modifying antirheumatic drugs (DMARDs, such as methotrexate, leflunomide). The nonsteroidal anti-inflammatory drugs and glucocorticoids mainly relieve symptoms, can not block or reverse joint damage, and can bring adverse reactions such as gastrointestinal tract, kidney, cardiovascular and metabolic damages (such as osteoporosis and hyperglycemia) after long-term use. Traditional chemical synthesis of DMARDs works slowly, and part of patients respond poorly or cannot tolerate them, and frequent hepatotoxicity, myelosuppression and gastrointestinal reactions require regular monitoring of blood routine and liver and kidney function. Thus, although existing drugs improve clinical symptoms of RA to some extent, there is still a great clinical need to develop new, efficient, low-toxicity drugs that interfere with RA progression due to the complex etiology, and the many drawbacks of existing therapies in terms of safety, tolerability, economy, and long-term disease control effects. Acute enteritis is an inflammatory disease of intestinal mucosa with rapid onset and short course, and is widely seen in people of all ages, especially in areas with poor sanitary conditions or people with low immunity. The disease is caused by infectious factors, and common pathogens include viruses (such as norovirus, rotavirus), bacteria (such as escherichia coli, salmonella, campylobacter, shigella) and parasites (such as cryptosporidium, amoeba histolytica). In addition, non-infectious causes such as improper diet, drug irritation (non-steroidal anti-inflammatory drugs, antibiotic-associated enteritis), toxin intake, and stress state of the body are not ignored. The pathogenic factors cause imbalance of intestinal secretion and absorption, mucosal congestion and edema, and even erosion and hemorrhage by destroying intestinal epithelial barrier function, activating local immune response and pro-inflammatory signaling pathway. From the clinical manifestation, patients with acute enteritis are usually characterized by watery or watery stool, and the times of defecation are obviously increased every day, and abdominal pain (mostly colic or diffuse), nausea, vomiting, fever and tenesmus are often accompanied. With an exacerbation of inflammation or an invasive pathogen infection, patients may develop more severe symptoms including hematochezia (manifested by a bright red or dark red blood mixed in the stool), weight loss due to systemic consumption and malabsorption, and a reduction in colon length reflecting overall inflammatory contracture or oedema remodeling of the colon. Serious patients can suffer from dehydration, metabolic acidosis or hypovolemic shock due to loss of a large amount of water and electrolyte, and especially form a great threat to infants, the elderly and patients with basic diseases. The course of the disease generally self-eases over days to two weeks, but some cases may persist or shift to chronic processes. Currently, conventional therapeutic strategies for acute enteritis are mainly symptomatic support, mainly comprising oral or intravenous fluid infusion to correct water electrolyte disorders, antidiarrheal agents (such as montmorillonite powder, loperamide) to reduce the number of bowel movements, and antibiotics for bacterial infections. However,